Fierce Pharma
JANUARY 9, 2023
JPM23, Day 1: BMS touts new launches as patent cliff looms; Regeneron's Eylea sales disappoint. esagonowsky. Mon, 01/09/2023 - 09:55.
MedCity News
JANUARY 12, 2023
UC Davis Health announced the first startup to come out of its health tech innovation incubator. The company, named WellCent, is a platform that allows patients and caregivers to onboard medical devices into their home and access digital health resources.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JANUARY 13, 2023
Health Canada has granted approval to Enhertu (trastuzumab deruxtecan) to treat unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer. Enhertu has been approved to treat HER2-low breast cancer adult patients who have previously received at least one line of chemotherapy in the metastatic setting or who have seen disease recurrence during or within six months after the adjuvant chemotherapy.
European Pharmaceutical Review
JANUARY 11, 2023
Machine learning models used to guide the design of long-acting injectable drug formulations have been successfully tested by scientists at the University of Toronto. The research results signal the potential for machine to reduce reliance on trial-and-error testing, which slows the development of long-acting injectables (LAIs). The study was published Nature Communications and is one of the first to apply machine learning techniques to the design of polymeric long-acting injectable drug formula
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
JANUARY 9, 2023
JPM23: Moderna reaped $18.4B in COVID vaccine sales last year, projects at least $5B in 2023. kdunleavy. Mon, 01/09/2023 - 10:34.
MedCity News
JANUARY 12, 2023
California’s Office of the Attorney General contends that drugmakers and pharmacy benefit managers work together to “aggressively raise the list price of insulin in lockstep with each other to artificial levels.” Insulin manufacturers deny the allegations, pointing to availability of lower-cost versions of their products.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Pharmaceutical Technology
JANUARY 8, 2023
In 2023, the pharmaceutical industry will mark 20 years since Xolair, an anti-IgE antibody, became the first biologic approved to treat asthma. Since then, the US FDA, EMA, and other agencies have approved several biologic antibodies targeting the inflammatory cytokines IL-4, IL-13, IL-5, and others for asthma. Approaches like bronchodilator inhalers focus on treating both asthma and chronic obstructive pulmonary disease (COPD).
Fierce Pharma
JANUARY 10, 2023
JPM23: Pfizer entering the 'most important' 18-month stretch in company history, CEO says. esagonowsky. Tue, 01/10/2023 - 08:51.
MedCity News
JANUARY 10, 2023
Nest Genomics just closed a $8.5 million seed financing round. The company provides the software infrastructure needed for health systems, clinics, drugmakers and payers to launch and scale genomic programs. It also provides tools for patients to easily access their genetic information.
pharmaphorum
JANUARY 11, 2023
Over the past few decades, data generation has veritably exploded. However, the ‘Big Data paradigm’ is not so much concerned with the volume of that data, but how businesses and, indeed, industries can derive meaningful insights from what has become a glut of information. With the currently popular approach to artificial intelligence (AI) focussing on the Big Data paradigm, also, pharmaphorum spoke with Adityo Prakash, CEO of Verseon, about the whys and wherefores, delving deeper into the proces
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
PharmExec
JANUARY 11, 2023
As new forms of cell and gene therapies continue to be developed, life sciences companies and payers need to find alternative ways to pay for these expensive treatments. Value-based contracts, though slow to gain traction so far, may provide the solution these groups are looking for.
Fierce Pharma
JANUARY 10, 2023
JPM23: Novavax hopes end of COVID emergency—and open vaccine market—will help it grow market share. aarmstrong. Tue, 01/10/2023 - 10:24.
MedCity News
JANUARY 9, 2023
There are several trends to watch out for in the substance use disorder space in 2023, according to CHESS Health’s CEO Hans Morefield. These trends include rising addiction rates and increased comfort in virtual health.
pharmaphorum
JANUARY 9, 2023
Novartis’ programme providing free access to its spinal muscular atrophy (SMA) gene therapy Zolgensma is being scaled back to a dozen countries worldwide, according to the company. First introduced in 2020, the global Managed Access Programme (gMAP) has provided Zolgensma (onasemnogene abeparvovec) free of charge to nearly 300 children with the genetic disorder across 36 countries where the therapy has not yet received approval or in which no formal access pathway exists.
European Pharmaceutical Review
JANUARY 13, 2023
The European Pharmacopoeia (Ph. Eur.) Commission (EPC) adopted the revised general monographs 2034 and 2619 , at its 174th session in November 2022 , which now includes a paragraph explaining the Ph. Eur. approach to the control of N -nitrosamine impurities. A paragraph on N -nitrosamines has been added to Substances for pharmaceutical use (2034) under ‘Production’: “ N -Nitrosamines.
Fierce Pharma
JANUARY 10, 2023
JPM23, Day 2: Takeda readies for dengue vaccine launch; Merck touts recent deals. kdunleavy. Tue, 01/10/2023 - 06:24.
MedCity News
JANUARY 11, 2023
In a media briefing during the J.P. Morgan Healthcare Conference in San Francisco, Paul Hudson said unlike Sanofi, large pharma companies with top-selling drugs have a portfolio akin to a leaky bathtub because in a few years, they will have to replace much of that revenue as drug patents expire.
pharmaphorum
JANUARY 10, 2023
mRNA specialist BioNTech has driven its partnership with UK artificial intelligence InstaDeep into top gear, agreeing to buy the company outright in a cash and equity deal that values it at up to £562 million ($683 million). The deal , billed as BioNTech’s largest to date and unveiled at the JP Morgan healthcare conference today, includes $362 million upfront with another £200 million on offer if performance targets are met.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
European Pharmaceutical Review
JANUARY 11, 2023
The largest microbiome study conducted at the highest resolution concluded the gut microbiome is involved in multiple pathways in the pathogenesis of Parkinson’s disease (PD). The findings, published in Nature Communications , show a wide imbalance in microbiome composition in people with Parkinson’s. Investigators at the University of Alabama at Birmingham, US employed metagenomics, the study of genetic material recovered directly from the stool microbiome of individuals with PD and neurologica
Fierce Pharma
JANUARY 11, 2023
JPM23: Is GSK’s 15-day accelerated approval withdrawal the new normal? Hear FDA commissioner Califf’s response. esagonowsky. Wed, 01/11/2023 - 10:34.
MedCity News
JANUARY 13, 2023
The FDA approved a change in Rybelsus’s label, allowing the drug to be used as an initial therapy for type 2 diabetes patients. The once-daily pill has already become a blockbuster product for Novo Nordisk.
pharmaphorum
JANUARY 10, 2023
Astellas has licensed rights to a drug developed by Selecta Biosciences that could make more patients eligible for treatment with its gene therapy for inherited neuromuscular disorder Pompe disease. The exclusive deal – which includes an upfront payment of $10 million and up to $340 million in milestone payments at the back end – covers the use of Selecta’s immunoglobulin G (IgG) protease drug IdeXork (Xork) alongside Astellas’ AT845, currently in the phase 1/2 FORTIS study in late-o
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
European Pharmaceutical Review
JANUARY 12, 2023
The European Commission (EC) has approved Xofluza ® (baloxavir marboxil) in children aged one year and above for uncomplicated influenza and post-exposure prophylaxis of influenza. . The European Commission’s approval. The agency’s regulatory approval, based on the results of two Phase III studies, marks the first single-dose, oral influenza medicine approved in Europe for children.
Fierce Pharma
JANUARY 11, 2023
AstraZeneca's first-in-class rescue inhaler Airsupra wins FDA nod—but only for adult use. esagonowsky. Wed, 01/11/2023 - 09:03.
MedCity News
JANUARY 13, 2023
The funding round was led by 8VC and included participation from Chelsea Clinton’s fund, Metrodora; the Female Founders Fund; Collaborative Fund; and Alumni Ventures. In total, Oula has raised $22.3 million. The company plans to use the funds to grow in its New York market and add more services.
pharmaphorum
JANUARY 9, 2023
We’re preparing to start JP Morgan week with a busy day Monday, with day 1 of the Informa Biotech Showcase, including a dedicated mini-event on Cell and Gene Therapy in the morning. Then in the evening, we’ll be at STAT@JPM for presentations by event sponsor GSK as well as the guest of honour: FDA Commissioner Robert Califf. Check below for updates throughout the day.
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
European Pharmaceutical Review
JANUARY 12, 2023
The Sustainable Market Initiative’s (SMI) 2022 Terra Carta Seal , which recognises global companies who are driving innovation and leadership within their industry, has been awarded to pharmaceutical companies GlaxoSmithKline PLC, Sanofi, and Samsung Biologics. Launched in January 2021, Terra Carta is a sustainability recovery plan for Nature, People and Planet.
Fierce Pharma
JANUARY 11, 2023
JPM23: GSK's Luke Miels on RSV and mRNA vaccines, Blenrep and Zejula withdrawals, plus more. qanderson. Wed, 01/11/2023 - 17:28.
MedCity News
JANUARY 8, 2023
Tim Barry, CEO of VillageMD, is encouraged by the shift he’s seeing to value-based care, but is worried that new technologies could create a fragmented system. He made these comments after the value-based company announced Thursday that it completed its $8.9 billion acquisition of Summit Health-City MD.
pharmaphorum
JANUARY 8, 2023
Before the main event at JP Morgan 2023 even kicks off, we’re checking out the Sachs Associates Neuroscience Innovation Forum on Sunday. Speakers from Lilly, Boehringer Ingelheim, Takeda, and many more pharma firms big and small will present on key trends and developments in one of the most exciting areas of pharmaceutical and digital innovation. We’ll also wander over to the UC Davis Health Future & Health CEO Summit a little later this afternoon.
Expert insights. Personalized for you.
345 
Let's personalize your content